



S1 Fig. Ponatinib is effective against imatinib-resistant CML cells (MYL-R).

MYL and MYL-R cells were cultured in triplicate in 96-well plates with increasing concentrations of ponatinib for 72 hours, and cell viability was assessed by MTS assay. MYL and MYL-R showed no difference in ponatinib sensitivity with IC₅₀ values of ~1.3 nM and ~1.2 nM respectively.